# Description:
## Columns in Dataset:

- **SampleID:** Unique identifier for each sample
- **SourceStudy:** Literature source or synthetic category (e.g., Ghasemi2025Adapted, PNIPAMResearchStudies, SyntheticTrainingData)
- **LCSTdegC:** Lower Critical Solution Temperature (°C)
- **TemperaturedegC:** Experimental temperature (°C)
- **pH:** Medium or buffer pH
- **PolymerConcmgml**: Polymer concentration (mg/ml)
- **DoxorubicinConcugml**: Drug concentration (μg/ml, typically doxorubicin)
- **CrosslinkerRatio:** Fractional ratio of crosslinker (0.021–0.998)
- **ParticleSizenm:** Particle size (nm)
- **DrugRelease72hpercent:** % released in 72 hours
- **CellViability24hpercent:** % viability at 24 hours (biocompatibility)
- **Hemolysispercent:** % hemolysis (red blood cell damage)
- **IC50ugml:** IC50 concentration for cytotoxicity (μg/ml)
- **LCSTEfficiency, ViabilityScore:** Derived/summary metrics

## Parameter Ranges:
- **Temperature:** 25–50 °C
- **pH:** 4.0–8.0
- **Polymer Conc:** 0.1–24.9 mg/ml
- **Drug Conc:** 1–499 μg/ml
- **Crosslinker Ratio:** 0.021–0.998
- **Particle Size:** 40.5–499.9 nm
- **Drug Release:** 23.3–98%
- **Cell Viability:** 75.6–95%
- **Hemolysis:** 2.1–11.3%
- **IC50:** 28.1–163.7 μg/ml

## Data Sources and Categories:
- **Ghasemi2025Adapted:** Nanogel studies; LCST, pH, temp, release, cell viability
- **Pytlikova2024Adapted:** Dual thermo/pH responsive nanoparticles
- **PNIPAMResearchStudies:** PNIPAM-based thermoresponsive research
- **ThermoresponsiveHydrogelPapers:** Hydrogel swelling and release systems
- **DrugDeliveryStudies:** Doxorubicin encapsulation, cell viability
- **SyntheticTrainingData:** Simulated data to expand coverage





